Possible Cancer Drop With Ozempic?

One large study of more than 111,000 women has stirred a simple but explosive question: could a weight-loss drug be linked to less breast cancer?

Story Snapshot

Researchers at Penn Medicine studied 111,646 women ages 45 to 80 with a body mass index of 25 or higher.^[4]
Women who used GLP-1 drugs had lower breast cancer odds than women who did not.^[4]
The study was observational, so it cannot prove the drugs caused the lower risk.^[4]
Experts say the result is promising, but far from ready for prevention advice.^[4]^[10]

What The Penn Study Found

Penn Medicine reviewed electronic health records from January 2022 through June 2025 and found a lower rate of new breast cancer among women who took glucagon-like peptide-1 drugs, often called GLP-1s.^[4] In the matched group, the odds were 30.5 percent lower, and in the full group, the odds were 35.1 percent lower.^[4] The researchers matched users and non-users by age, race, ethnicity, body mass index, breast density, and diabetes status to reduce bias.^[4]

The raw numbers matter because they slow the hype down. Breast cancer still appeared in both groups, and the absolute difference was small, with about 2.3 percent of non-users and 1.6 percent of users developing cancer in the reporting cited by television coverage. That is a real signal, but it is not a miracle number.^[4] The result is best read as a clue, not a verdict.

Why Scientists Are Paying Attention

GLP-1 drugs already reshape how doctors think about weight, diabetes, and heart disease. That makes them interesting in cancer research, because excess body fat can raise estrogen levels, drive inflammation, and increase breast cancer risk.^[15] Penn researchers suggested a biologic path that could connect the drugs to lower risk, including less inflammation and possible effects on cancer-related pathways.^[4] That theory is plausible, but plausibility is not proof.

The Penn team also said the findings may justify a future multisite clinical trial in high-risk women.^[4]^[11] That step matters because randomized trials can separate true drug effects from the fog of who gets treated, who loses weight, and who already has better health care access. Until then, the study sits in the familiar middle ground of medicine: interesting enough to study, too early to sell as prevention.

Why Skeptics Are Not Convinced

The main weakness is the design. This was a retrospective study, which means it looked backward at records instead of following women forward in a trial.^[4] The lead author said the work “does not definitively confirm an association,” and she noted that prospective data, the gold standard, is still missing.^[4] That is the right scientific caution, and it should not be brushed aside because the headline is exciting.

Critics also point to missing factors that can distort cancer risk, including income, exercise, alcohol use, family history, genetic risk, and other medicines. Those were not fully controlled in the analysis discussed by outside experts.[CBS Mornings transcript] A few people may see a 30 percent relative drop and call it huge, but the practical difference is still small. That gap between relative risk and real-world impact is where bad health headlines are born.

What This Means For Patients Right Now

No one should hear this study and rush to use GLP-1 drugs as breast cancer prevention. The evidence does not support that jump. The best current reading is narrower: these drugs may someday help lower risk, but that idea still needs trial proof.^[4]^[10] Other research has been more neutral, including a review of randomized trials that found GLP-1 drugs likely have little or no effect on overall obesity-linked cancer risk.^[17]

That tension is exactly why this story matters. Science often starts with a pattern, then tests whether the pattern survives a harder look. Here, the pattern is real enough to attract serious attention, but not strong enough to end the debate. For women worried about breast cancer, the practical levers remain the old ones: weight management, screening, and talking with a doctor about personal risk.^[4]^[15]